课题基金 / 基金详情

Targeting the degradation of the cyclin-dependent kinase inhibitor p21 as a novel approach to cancer therapy

Targeting the degradation of the cyclin-dependent kinase inhibitor p21 as a novel approach to cancer therapy
以细胞周期蛋白依赖性激酶抑制剂 p21 的降解为目标作为癌症治疗的新方法
批准号：
212876
负责人：
Meloche Sylvain
金额：
$11.66万
依托单位：
Institute for Research in Immunology and Cancer (Montreal, QC)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2010
资助国家：
加拿大
项目状态：
已结题
起止时间：
2010-09-01 至 2011-09-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=212876&lang=en
关键词：
Cancer Cell Cycle Cyclin-Dependent Kinase Inhibitors Drug Development Medicinal Chemistry Ubiquitin-Proteasome System

项目摘要

项目成果

Meloche Sylvain的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The proliferation of cells is regulated by a complex network of biochemical reactions that ensure that each cell division step is performed correctly and in proper sequence. Among these reactions is the timed degradation of cellular regulatory proteins by
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role and therapeutic potential of the atypical MAP kinase ERK3 in basal-like breast cancer progression
Development and preclinical validation of first-in-class dual inhibitors of the atypical MAP kinases ERK3 and ERK4
Role and therapeutic potential of ERK3/ERK4 MAP kinases in acute kidney injury
Regulation, downstream targets and functional specificity of the MAP kinases ERK1 and ERK2
海外基金